AZ bets big on biologics with $285M Swedish facility

AstraZeneca ($AZN), trying to turn its sales performance around, has some biologics launches on the horizon. But to accommodate them, it needs more manufacturing capacity, and it thinks a new $285 million plant in Sweden will do the trick. More from FiercePharma

Suggested Articles

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.

AstraZeneca partners with actor and asthma sufferer Tony Hale to raise awareness about eosinophilic asthma and blood testing to diagnose it.

Even at its maximum, Roche's oral Evrysdi comes at a discount to Spinraza's low-end, maintenance list price.